In the present study, we found that meridianins at the dose used are in a correct balance to avoid detrimental effects caused by excessive GSK3β manipulation, reinforcing the need to further investigate its applicability as a potential treatment for AD in the near future. The gene discussed is GSK3B; the disease is Alzheimer disease.